A simple staging system using biomarkers for wild‐type transthyretin amyloid cardiomyopathy in Japan
Abstract Aims It has been reported that a staging system combining N‐terminal pro‐B‐type natriuretic peptide and high‐sensitivity troponin T (hs‐cTnT) or estimated glomerular filtration rate (eGFR) is useful in patients with wild‐type transthyretin amyloid cardiomyopathy (ATTRwt‐CM). However, these...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-06-01
|
| Series: | ESC Heart Failure |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/ehf2.13847 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832540325077319680 |
|---|---|
| author | Naoya Nakashima Seiji Takashio Mami Morioka Masato Nishi Toshihiro Yamada Kyoko Hirakawa Masanobu Ishii Noriaki Tabata Kenshi Yamanaga Koichiro Fujisue Daisuke Sueta Hisanori Kanazawa Tadashi Hoshiyama Shinsuke Hanatani Satoshi Araki Hiroki Usuku Eiichiro Yamamoto Mitsuharu Ueda Kenichi Matsushita Kenichi Tsujita |
| author_facet | Naoya Nakashima Seiji Takashio Mami Morioka Masato Nishi Toshihiro Yamada Kyoko Hirakawa Masanobu Ishii Noriaki Tabata Kenshi Yamanaga Koichiro Fujisue Daisuke Sueta Hisanori Kanazawa Tadashi Hoshiyama Shinsuke Hanatani Satoshi Araki Hiroki Usuku Eiichiro Yamamoto Mitsuharu Ueda Kenichi Matsushita Kenichi Tsujita |
| author_sort | Naoya Nakashima |
| collection | DOAJ |
| description | Abstract Aims It has been reported that a staging system combining N‐terminal pro‐B‐type natriuretic peptide and high‐sensitivity troponin T (hs‐cTnT) or estimated glomerular filtration rate (eGFR) is useful in patients with wild‐type transthyretin amyloid cardiomyopathy (ATTRwt‐CM). However, these studies were mainly conducted in Western countries, and their usefulness for the Japanese population is unclear. We examined and validated the staging system using hs‐cTnT, eGFR, and B‐type natriuretic peptide (BNP) in Japanese patients with ATTRwt‐CM. Methods and results We retrospectively evaluated 176 patients with ATTRwt‐CM. The cut‐off values of hs‐cTnT and eGFR were selected as 0.05 ng/mL and 45 mL/min/1.73 m2, respectively, based on a previous report. The optimal cut‐off value of BNP was 255.6 pg/mL to predict all‐cause mortality (sensitivity, 75%; specificity, 58%; area under the curve, 0.69; 95% confidence interval [CI], 0.61–0.78; P < 0.001) based on a receiver operating characteristic curve. We defined the cut‐off value of BNP as 250 pg/mL. Increased hs‐cTnT (>0.05 ng/mL) and BNP (>250 pg/mL) and decreased eGFR (<45 mL/min/1.73 m2) were significant predictors of poor prognosis (P < 0.05). We calculated the score by adding 1 point if hs‐cTnT and BNP levels increased or eGFR decreased by more than the cut‐off value. The hazard ratio of all‐cause death adjusted by age and sex, using score 0 as a reference, was 0.44 (95% CI 0.08–2.49, P = 0.44) for score 1, 3.69 (95% CI 1.21–11.21, P = 0.02) for score 2, and 5.40 (95% CI 1.57–18.54, P = 0.007) for score 3. We divided patients into a low score group (0–1 point) and high score group (2–3 points). Kaplan–Meier analyses revealed significant differences in all‐cause death and rehospitalization for heart failure (log rank test; P < 0.001), and after adjusting for sex and age, the hazard ratio of all‐cause death was 6.96 (95% Cl 2.88–16.83, P < 0.001) and that for rehospitalization for heart failure was 4.27 (95% Cl 2.26–8.07, P < 0.001) in the high‐risk group, compared with those in the low‐risk group. The median survival period was 32.0 months in the high‐risk group. Conclusions This simple staging system, which combines hs‐cTnT, BNP, and eGFR, was useful for predicting prognosis in Japanese patients with ATTRwt‐CM. This system can objectively evaluate the disease progression of ATTRwt‐CM and may be useful for patient selection for disease‐modifying therapy. |
| format | Article |
| id | doaj-art-6a9bebb62b1a4a5fbfa1fd3d46a14b82 |
| institution | Kabale University |
| issn | 2055-5822 |
| language | English |
| publishDate | 2022-06-01 |
| publisher | Wiley |
| record_format | Article |
| series | ESC Heart Failure |
| spelling | doaj-art-6a9bebb62b1a4a5fbfa1fd3d46a14b822025-02-05T05:22:10ZengWileyESC Heart Failure2055-58222022-06-01931731173910.1002/ehf2.13847A simple staging system using biomarkers for wild‐type transthyretin amyloid cardiomyopathy in JapanNaoya Nakashima0Seiji Takashio1Mami Morioka2Masato Nishi3Toshihiro Yamada4Kyoko Hirakawa5Masanobu Ishii6Noriaki Tabata7Kenshi Yamanaga8Koichiro Fujisue9Daisuke Sueta10Hisanori Kanazawa11Tadashi Hoshiyama12Shinsuke Hanatani13Satoshi Araki14Hiroki Usuku15Eiichiro Yamamoto16Mitsuharu Ueda17Kenichi Matsushita18Kenichi Tsujita19Department of Cardiovascular Medicine, Graduate School of Medical Sciences Kumamoto University 1‐1‐1 Honjo, Chou‐ku Kumamoto 860‐8556 JapanDepartment of Cardiovascular Medicine, Graduate School of Medical Sciences Kumamoto University 1‐1‐1 Honjo, Chou‐ku Kumamoto 860‐8556 JapanDepartment of Cardiovascular Medicine, Graduate School of Medical Sciences Kumamoto University 1‐1‐1 Honjo, Chou‐ku Kumamoto 860‐8556 JapanDepartment of Cardiovascular Medicine, Graduate School of Medical Sciences Kumamoto University 1‐1‐1 Honjo, Chou‐ku Kumamoto 860‐8556 JapanDepartment of Cardiovascular Medicine, Graduate School of Medical Sciences Kumamoto University 1‐1‐1 Honjo, Chou‐ku Kumamoto 860‐8556 JapanDepartment of Cardiovascular Medicine, Graduate School of Medical Sciences Kumamoto University 1‐1‐1 Honjo, Chou‐ku Kumamoto 860‐8556 JapanDepartment of Cardiovascular Medicine, Graduate School of Medical Sciences Kumamoto University 1‐1‐1 Honjo, Chou‐ku Kumamoto 860‐8556 JapanDepartment of Cardiovascular Medicine, Graduate School of Medical Sciences Kumamoto University 1‐1‐1 Honjo, Chou‐ku Kumamoto 860‐8556 JapanDepartment of Cardiovascular Medicine, Graduate School of Medical Sciences Kumamoto University 1‐1‐1 Honjo, Chou‐ku Kumamoto 860‐8556 JapanDepartment of Cardiovascular Medicine, Graduate School of Medical Sciences Kumamoto University 1‐1‐1 Honjo, Chou‐ku Kumamoto 860‐8556 JapanDepartment of Cardiovascular Medicine, Graduate School of Medical Sciences Kumamoto University 1‐1‐1 Honjo, Chou‐ku Kumamoto 860‐8556 JapanDepartment of Cardiovascular Medicine, Graduate School of Medical Sciences Kumamoto University 1‐1‐1 Honjo, Chou‐ku Kumamoto 860‐8556 JapanDepartment of Cardiovascular Medicine, Graduate School of Medical Sciences Kumamoto University 1‐1‐1 Honjo, Chou‐ku Kumamoto 860‐8556 JapanDepartment of Cardiovascular Medicine, Graduate School of Medical Sciences Kumamoto University 1‐1‐1 Honjo, Chou‐ku Kumamoto 860‐8556 JapanDepartment of Cardiovascular Medicine, Graduate School of Medical Sciences Kumamoto University 1‐1‐1 Honjo, Chou‐ku Kumamoto 860‐8556 JapanDepartment of Cardiovascular Medicine, Graduate School of Medical Sciences Kumamoto University 1‐1‐1 Honjo, Chou‐ku Kumamoto 860‐8556 JapanDepartment of Cardiovascular Medicine, Graduate School of Medical Sciences Kumamoto University 1‐1‐1 Honjo, Chou‐ku Kumamoto 860‐8556 JapanDepartment of Neurology, Graduate School of Medical Sciences Kumamoto University Kumamoto JapanDepartment of Cardiovascular Medicine, Graduate School of Medical Sciences Kumamoto University 1‐1‐1 Honjo, Chou‐ku Kumamoto 860‐8556 JapanDepartment of Cardiovascular Medicine, Graduate School of Medical Sciences Kumamoto University 1‐1‐1 Honjo, Chou‐ku Kumamoto 860‐8556 JapanAbstract Aims It has been reported that a staging system combining N‐terminal pro‐B‐type natriuretic peptide and high‐sensitivity troponin T (hs‐cTnT) or estimated glomerular filtration rate (eGFR) is useful in patients with wild‐type transthyretin amyloid cardiomyopathy (ATTRwt‐CM). However, these studies were mainly conducted in Western countries, and their usefulness for the Japanese population is unclear. We examined and validated the staging system using hs‐cTnT, eGFR, and B‐type natriuretic peptide (BNP) in Japanese patients with ATTRwt‐CM. Methods and results We retrospectively evaluated 176 patients with ATTRwt‐CM. The cut‐off values of hs‐cTnT and eGFR were selected as 0.05 ng/mL and 45 mL/min/1.73 m2, respectively, based on a previous report. The optimal cut‐off value of BNP was 255.6 pg/mL to predict all‐cause mortality (sensitivity, 75%; specificity, 58%; area under the curve, 0.69; 95% confidence interval [CI], 0.61–0.78; P < 0.001) based on a receiver operating characteristic curve. We defined the cut‐off value of BNP as 250 pg/mL. Increased hs‐cTnT (>0.05 ng/mL) and BNP (>250 pg/mL) and decreased eGFR (<45 mL/min/1.73 m2) were significant predictors of poor prognosis (P < 0.05). We calculated the score by adding 1 point if hs‐cTnT and BNP levels increased or eGFR decreased by more than the cut‐off value. The hazard ratio of all‐cause death adjusted by age and sex, using score 0 as a reference, was 0.44 (95% CI 0.08–2.49, P = 0.44) for score 1, 3.69 (95% CI 1.21–11.21, P = 0.02) for score 2, and 5.40 (95% CI 1.57–18.54, P = 0.007) for score 3. We divided patients into a low score group (0–1 point) and high score group (2–3 points). Kaplan–Meier analyses revealed significant differences in all‐cause death and rehospitalization for heart failure (log rank test; P < 0.001), and after adjusting for sex and age, the hazard ratio of all‐cause death was 6.96 (95% Cl 2.88–16.83, P < 0.001) and that for rehospitalization for heart failure was 4.27 (95% Cl 2.26–8.07, P < 0.001) in the high‐risk group, compared with those in the low‐risk group. The median survival period was 32.0 months in the high‐risk group. Conclusions This simple staging system, which combines hs‐cTnT, BNP, and eGFR, was useful for predicting prognosis in Japanese patients with ATTRwt‐CM. This system can objectively evaluate the disease progression of ATTRwt‐CM and may be useful for patient selection for disease‐modifying therapy.https://doi.org/10.1002/ehf2.13847TransthyretinAmyloid cardiomyopathyStagingBiomarker |
| spellingShingle | Naoya Nakashima Seiji Takashio Mami Morioka Masato Nishi Toshihiro Yamada Kyoko Hirakawa Masanobu Ishii Noriaki Tabata Kenshi Yamanaga Koichiro Fujisue Daisuke Sueta Hisanori Kanazawa Tadashi Hoshiyama Shinsuke Hanatani Satoshi Araki Hiroki Usuku Eiichiro Yamamoto Mitsuharu Ueda Kenichi Matsushita Kenichi Tsujita A simple staging system using biomarkers for wild‐type transthyretin amyloid cardiomyopathy in Japan ESC Heart Failure Transthyretin Amyloid cardiomyopathy Staging Biomarker |
| title | A simple staging system using biomarkers for wild‐type transthyretin amyloid cardiomyopathy in Japan |
| title_full | A simple staging system using biomarkers for wild‐type transthyretin amyloid cardiomyopathy in Japan |
| title_fullStr | A simple staging system using biomarkers for wild‐type transthyretin amyloid cardiomyopathy in Japan |
| title_full_unstemmed | A simple staging system using biomarkers for wild‐type transthyretin amyloid cardiomyopathy in Japan |
| title_short | A simple staging system using biomarkers for wild‐type transthyretin amyloid cardiomyopathy in Japan |
| title_sort | simple staging system using biomarkers for wild type transthyretin amyloid cardiomyopathy in japan |
| topic | Transthyretin Amyloid cardiomyopathy Staging Biomarker |
| url | https://doi.org/10.1002/ehf2.13847 |
| work_keys_str_mv | AT naoyanakashima asimplestagingsystemusingbiomarkersforwildtypetransthyretinamyloidcardiomyopathyinjapan AT seijitakashio asimplestagingsystemusingbiomarkersforwildtypetransthyretinamyloidcardiomyopathyinjapan AT mamimorioka asimplestagingsystemusingbiomarkersforwildtypetransthyretinamyloidcardiomyopathyinjapan AT masatonishi asimplestagingsystemusingbiomarkersforwildtypetransthyretinamyloidcardiomyopathyinjapan AT toshihiroyamada asimplestagingsystemusingbiomarkersforwildtypetransthyretinamyloidcardiomyopathyinjapan AT kyokohirakawa asimplestagingsystemusingbiomarkersforwildtypetransthyretinamyloidcardiomyopathyinjapan AT masanobuishii asimplestagingsystemusingbiomarkersforwildtypetransthyretinamyloidcardiomyopathyinjapan AT noriakitabata asimplestagingsystemusingbiomarkersforwildtypetransthyretinamyloidcardiomyopathyinjapan AT kenshiyamanaga asimplestagingsystemusingbiomarkersforwildtypetransthyretinamyloidcardiomyopathyinjapan AT koichirofujisue asimplestagingsystemusingbiomarkersforwildtypetransthyretinamyloidcardiomyopathyinjapan AT daisukesueta asimplestagingsystemusingbiomarkersforwildtypetransthyretinamyloidcardiomyopathyinjapan AT hisanorikanazawa asimplestagingsystemusingbiomarkersforwildtypetransthyretinamyloidcardiomyopathyinjapan AT tadashihoshiyama asimplestagingsystemusingbiomarkersforwildtypetransthyretinamyloidcardiomyopathyinjapan AT shinsukehanatani asimplestagingsystemusingbiomarkersforwildtypetransthyretinamyloidcardiomyopathyinjapan AT satoshiaraki asimplestagingsystemusingbiomarkersforwildtypetransthyretinamyloidcardiomyopathyinjapan AT hirokiusuku asimplestagingsystemusingbiomarkersforwildtypetransthyretinamyloidcardiomyopathyinjapan AT eiichiroyamamoto asimplestagingsystemusingbiomarkersforwildtypetransthyretinamyloidcardiomyopathyinjapan AT mitsuharuueda asimplestagingsystemusingbiomarkersforwildtypetransthyretinamyloidcardiomyopathyinjapan AT kenichimatsushita asimplestagingsystemusingbiomarkersforwildtypetransthyretinamyloidcardiomyopathyinjapan AT kenichitsujita asimplestagingsystemusingbiomarkersforwildtypetransthyretinamyloidcardiomyopathyinjapan AT naoyanakashima simplestagingsystemusingbiomarkersforwildtypetransthyretinamyloidcardiomyopathyinjapan AT seijitakashio simplestagingsystemusingbiomarkersforwildtypetransthyretinamyloidcardiomyopathyinjapan AT mamimorioka simplestagingsystemusingbiomarkersforwildtypetransthyretinamyloidcardiomyopathyinjapan AT masatonishi simplestagingsystemusingbiomarkersforwildtypetransthyretinamyloidcardiomyopathyinjapan AT toshihiroyamada simplestagingsystemusingbiomarkersforwildtypetransthyretinamyloidcardiomyopathyinjapan AT kyokohirakawa simplestagingsystemusingbiomarkersforwildtypetransthyretinamyloidcardiomyopathyinjapan AT masanobuishii simplestagingsystemusingbiomarkersforwildtypetransthyretinamyloidcardiomyopathyinjapan AT noriakitabata simplestagingsystemusingbiomarkersforwildtypetransthyretinamyloidcardiomyopathyinjapan AT kenshiyamanaga simplestagingsystemusingbiomarkersforwildtypetransthyretinamyloidcardiomyopathyinjapan AT koichirofujisue simplestagingsystemusingbiomarkersforwildtypetransthyretinamyloidcardiomyopathyinjapan AT daisukesueta simplestagingsystemusingbiomarkersforwildtypetransthyretinamyloidcardiomyopathyinjapan AT hisanorikanazawa simplestagingsystemusingbiomarkersforwildtypetransthyretinamyloidcardiomyopathyinjapan AT tadashihoshiyama simplestagingsystemusingbiomarkersforwildtypetransthyretinamyloidcardiomyopathyinjapan AT shinsukehanatani simplestagingsystemusingbiomarkersforwildtypetransthyretinamyloidcardiomyopathyinjapan AT satoshiaraki simplestagingsystemusingbiomarkersforwildtypetransthyretinamyloidcardiomyopathyinjapan AT hirokiusuku simplestagingsystemusingbiomarkersforwildtypetransthyretinamyloidcardiomyopathyinjapan AT eiichiroyamamoto simplestagingsystemusingbiomarkersforwildtypetransthyretinamyloidcardiomyopathyinjapan AT mitsuharuueda simplestagingsystemusingbiomarkersforwildtypetransthyretinamyloidcardiomyopathyinjapan AT kenichimatsushita simplestagingsystemusingbiomarkersforwildtypetransthyretinamyloidcardiomyopathyinjapan AT kenichitsujita simplestagingsystemusingbiomarkersforwildtypetransthyretinamyloidcardiomyopathyinjapan |